Kiora Pharmaceuticals (NASDAQ:KPRX) Announces Earnings Results, Misses Estimates By $0.90 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) posted its quarterly earnings data on Wednesday. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.90), FiscalAI reports.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX opened at $2.06 on Wednesday. The company has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $2.25. The firm has a market capitalization of $7.58 million, a price-to-earnings ratio of -0.99 and a beta of -0.80. Kiora Pharmaceuticals has a 52-week low of $1.76 and a 52-week high of $4.18.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP purchased a new stake in Kiora Pharmaceuticals in the 3rd quarter worth approximately $33,000. Renaissance Technologies LLC increased its stake in shares of Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after acquiring an additional 8,800 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Kiora Pharmaceuticals during the third quarter worth $125,000. Alyeska Investment Group L.P. purchased a new stake in shares of Kiora Pharmaceuticals during the fourth quarter worth $152,000. Finally, DRW Securities LLC boosted its position in Kiora Pharmaceuticals by 199.2% during the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after purchasing an additional 73,417 shares during the last quarter. Institutional investors and hedge funds own 76.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research report on Wednesday, January 28th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.